Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 7
Submit an article Journal homepage
1,960
Views
44
CrossRef citations to date
0
Altmetric
Original Research

Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma

Qian-Kun XieMinimally Invasive Interventional Division, Medical Imaging Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
,
Yu-Jie ZhaoMinimally Invasive Interventional Division, Medical Imaging Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China;Department of Clinical Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China
,
Tao PanDepartment of Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
,
Ning LyuMinimally Invasive Interventional Division, Medical Imaging Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
,
Lu-Wen MuMinimally Invasive Interventional Division, Medical Imaging Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
,
Shao-Long LiMinimally Invasive Interventional Division, Medical Imaging Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
,
Mu-De ShiCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
,
Zhen-Feng ZhangCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
,
Peng-Hui ZhouCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China
&
Ming ZhaoMinimally Invasive Interventional Division, Medical Imaging Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaCorrespondence[email protected]
 show all
Article: e1181252 | Received 03 Feb 2016, Accepted 15 Apr 2016, Published online: 30 Jun 2016

Citations (44)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Dina Omar Helmy, Fatma Khattab, Azza Elsayed Hegazy & Rania Mohamed Sabry. (2023) Immunohistochemical expression of immune check point protein PDL-1 in hepatocellular carcinoma denotes its prognostic significance and association with survival. Journal of Immunoassay and Immunochemistry 44:3, pages 213-228.
Read now
Ying Zhu, Xiang-Yu Wang, Yu Zhang, Da Xu, Jian Dong, Ze Zhang, Chen-He Yi, Hu-Liang Jia & Xin Yang. (2018) Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses. Cancer Management and Research 10, pages 4113-4123.
Read now
Yu-Jie Zhao, Wei-Peng Sun, Jian-Hong Peng, Yu-Xiang Deng, Yu-Jing Fang, Jun Huang, Hui-Zhong Zhang, De-Sen Wan, Jun-Zhong Lin & Zhi-Zhong Pan. (2018) Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. Cancer Management and Research 10, pages 1-11.
Read now

Articles from other publishers (41)

Seogsong Jeong, Woo-Young Shin & Yun Hwan Oh. (2023) Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. Frontiers in Endocrinology 14.
Crossref
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Akira Doi, Yuki Tahata, Kazuyoshi Ohkawa, Masahide Oshita, Masanori Miyazaki, Takayuki Yakushijin, Yasutoshi Nozaki, Kengo Matsumoto, Satoshi Tanaka, Akira Kaneko, Sadaharu Iio, Takatoshi Nawa, Yukinori Yamada, Naoki Morishita, Takeo Usui, Naoki Hiramatsu, Yoshinori Doi, Mitsuru Sakakibara, Kazuho Imanaka, Yuichi Yoshida, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi & Tetsuo Takehara. (2023) Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. PLOS ONE 18:2, pages e0281459.
Crossref
Yang Zhang, Zongjuan Li, Yixing Chen, Ping Yang, Yong Hu, Zhaochong Zeng & Shisuo Du. (2022) Higher serum sPD-L1 levels after radiotherapy indicate poor outcome in hepatocellular carcinoma patients. Translational Oncology 26, pages 101537.
Crossref
Ulrich Sommer, Celina Ebersbach, Alicia-Marie K. Beier, Gustavo B. Baretton, Christian Thomas, Angelika Borkowetz & Holger H. H. Erb. (2022) Influence of Androgen Deprivation Therapy on the PD-L1 Expression and Immune Activity in Prostate Cancer Tissue. Frontiers in Molecular Biosciences 9.
Crossref
Rosa Lombardi, Roberto Piciotti, Paola Dongiovanni, Marica Meroni, Silvia Fargion & Anna Ludovica Fracanzani. (2022) PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease. International Journal of Molecular Sciences 23:5, pages 2707.
Crossref
Guoying Zhou, Patrick P. C. Boor, Marco J. Bruno, Dave Sprengers & Jaap Kwekkeboom. (2021) Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. British Journal of Cancer 126:1, pages 10-23.
Crossref
Venkata Prasuja Nakka. 2022. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 215 223 .
Lin Sun, Luwen Mu, Jing Zhou, Wenjie Tang, Linqi Zhang, Sidong Xie, Jingbiao Chen & Jin Wang. (2021) Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunology, Immunotherapy 71:1, pages 25-38.
Crossref
Min Deng, Shao-Hua Li, Xu Fu, Xiao-Peng Yan, Jun Chen, Yu-Dong Qiu & Rong-Ping Guo. (2021) Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients. Cancer Cell International 21:1.
Crossref
Xiaopei Hao, Guangshun Sun, Yao Zhang, Xiangyi Kong, Dawei Rong, Jinhua Song, Weiwei Tang & Xuehao Wang. (2021) Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges. Frontiers in Cell and Developmental Biology 9.
Crossref
Thuzar Hla Shwe, Peraphan Pothacharoen, Thanyaluck Phitak, Benjawan Wudtiwai & Prachya Kongtawelert. (2021) Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells. International Journal of Molecular Sciences 22:16, pages 8755.
Crossref
Man Wu, Xueqing Xia, Jiemiao Hu, Natalie Wall Fowlkes & Shulin Li. (2021) WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression. Nature Communications 12:1.
Crossref
Wei Jiang, Tao Li, Jiaojiao Guo, Jingjing Wang, Lizhou Jia, Xiao shi, Tingting Yang, Ruonan Jiao, Xin Wei, Zhenqing Feng, Qi Tang & Guozhong Ji. (2021) Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma. Frontiers in Oncology 11.
Crossref
Tomoko Aoki, Naoshi Nishida, Kazuomi Ueshima, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Yasunori Minami, Akira Yamada, Keitaro Sofue, Masakatsu Tsurusaki & Masatoshi Kudo. (2021) Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer 10:6, pages 615-628.
Crossref
Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Yasunori Minami, Masakatsu Tsurusaki & Naoshi Nishida. (2020) Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade. Cancers 12:10, pages 3048.
Crossref
Sameer Ahamd Guru, Mamta P. Sumi, Rashid Mir, Ajaz Ahmad Waza, Musadiq Ahmad Bhat, Mariyam Zuberi, Promod Lali & Alpana Saxena. (2020) Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Human Cell 33:4, pages 1099-1111.
Crossref
Katsuya Noguchi, Takashi Shimomura, Yuya Ohuchi, Munetaka Ishiyama, Masanobu Shiga, Takeshi Mori, Yoshiki Katayama & Yuichiro Ueno. (2020) β-Galactosidase-Catalyzed Fluorescent Reporter Labeling of Living Cells for Sensitive Detection of Cell Surface Antigens. Bioconjugate Chemistry 31:7, pages 1740-1744.
Crossref
Hatem A. Elmezayen, Hirohisa Okabe, Yoshifumi Baba, Toshihiko Yusa, Rumi Itoyama, Yosuke Nakao, Takanobu Yamao, Naoki Umzaki, Masayo Tsukamoto, Yuki Kitano, Tatsunori Miyata, Kota Arima, Hiromitsu Hayashi, Katsunori Imai, Akira Chikamoto, Yo-ichi Yamashita & Hideo Baba. (2019) Clinical role of serum programmed death ligand 1 in patients with hepatocellular carcinoma: Where does it come from?. Surgery Today 50:6, pages 569-576.
Crossref
Xiao-Song Li, Jun-Wei Li, Hui Li & Tao Jiang. (2020) Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis. Bioscience Reports 40:4.
Crossref
Kumari Asha, Natalie Balfe & Neelam Sharma-Walia. (2020) Concurrent Control of the Kaposi's Sarcoma-Associated Herpesvirus Life Cycle through Chromatin Modulation and Host Hedgehog Signaling: a New Prospect for the Therapeutic Potential of Lipoxin A4. Journal of Virology 94:9.
Crossref
Ying-Chun Shen, Chia-Lang Hsu, Yung-Ming Jeng, Ming-Chih Ho, Cheng-Maw Ho, Ching-Ping Yeh, Chia-Yu Yeh, Meng-Chi Hsu, Ray-Heng Hu & Ann-Lii Cheng. (2020) Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma. Journal of Hepatology 72:3, pages 489-497.
Crossref
Elena Martin-Orozco, Ana Sanchez-Fernandez, Irene Ortiz-Parra & Maria Ayala-San Nicolas. (2019) WNT Signaling in Tumors: The Way to Evade Drugs and Immunity. Frontiers in Immunology 10.
Crossref
Zi-Qi Zhou, Jing-Jing Zhao, Qiu-Zhong Pan, Chang-Long Chen, Yuan Liu, Yan Tang, Qian Zhu, De-Sheng Weng & Jian-Chuan Xia. (2019) PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Yipin Lv, Yongliang Zhao, Xianhua Wang, Na Chen, Fangyuan Mao, Yongsheng Teng, Tingting Wang, Liusheng Peng, Jinyu Zhang, Ping Cheng, Yugang Liu, Hui Kong, Weisan Chen, Chuanjie Hao, Bin Han, Qiang Ma, Quanming Zou, Jun Chen & Yuan Zhuang. (2019) Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Gao-Min Liu, Xu-Gang Li & Yao-Min Zhang. (2019) Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis. Cancer Cell International 19:1.
Crossref
Yi-Ming Li, Jing-Min Yu, Zhen-Yu Liu, Hai-Jiao Yang, Juan Tang & Zhi-Nan Chen. (2019) Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 20:20, pages 5138.
Crossref
Zhaoyun Zong, Jiahuan Zou, Rudi Mao, Chao Ma, Na Li, Jianing Wang, Xiaoyan Wang, Huaiyu Zhou, Lining Zhang & Yongyu Shi. (2019) M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling. Frontiers in Immunology 10.
Crossref
Boyang Chang, Tao Huang, Huajun Wei, Lujun Shen, Duo Zhu, Wenjun He, Qifeng Chen, Huihua Zhang, Yunjian Li, Ruopan Huang, Wang Li & Peihong Wu. (2018) The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy 68:3, pages 353-363.
Crossref
Christian Ihling, Bartholomew Naughton, Yue Zhang, P. Alexander Rolfe, Eveline Frick-Krieger, Luigi M. Terracciano & Isabelle Dussault. (2019) Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma. Frontiers in Medicine 6.
Crossref
Xue Han, Yang-kui Gu, Shao-long Li, Hao Chen, Min-shan Chen, Qing-qing Cai, Han-xia Deng, Meng-xuan Zuo & Jin-hua Huang. (2018) Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 145:2, pages 303-312.
Crossref
Xuezhong Xu, Yulin Tan, Yan Qian, Wenbo Xue, Yibo Wang, Jianguo Du, Lei Jin & Wei Ding. (2019) Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma. Medicine 98:2, pages e13923.
Crossref
Shaolong Li, Xue Han, Ning Lyu, Qiankun Xie, Haijing Deng, Luwen Mu, Tao Pan, Xin Huang, Xia Wang, Yuanyuan Shi & Ming Zhao. (2018) Mechanism and prognostic value of indoleamine 2,3‐dioxygenase 1 expressed in hepatocellular carcinoma. Cancer Science 109:12, pages 3726-3736.
Crossref
Wei Ding, Xuezhong Xu, Yan Qian, Wenbo Xue, Yibo Wang, Jianguo Du, Lei Jin & Yulin Tan. (2018) Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma. Medicine 97:50, pages e13301.
Crossref
Jing-Hua Li, Wei-Jie Ma, Gang-Gang Wang, Xiang Jiang, Xi Chen, Long Wu, Zhi-Su Liu, Xian-Tao Zeng, Fu-Ling Zhou & Yu-Feng Yuan. (2018) Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis. Frontiers in Immunology 9.
Crossref
Jiahuan Zou, Mengwei Zhuang, Xiaopeng Yu, Na Li, Rudi Mao, Zhida Wang, Jianing Wang, Xiaoyan Wang, Huaiyu Zhou, Lining Zhang & Yongyu Shi. (2018) MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells. Molecular Immunology 101, pages 203-209.
Crossref
Yiting Wang, Huanbin Wang, Han Yao, Chushu Li, Jing-Yuan Fang & Jie Xu. (2018) Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion. Frontiers in Pharmacology 9.
Crossref
Marc Ringelhan, Dominik Pfister, Tracy O’Connor, Eli Pikarsky & Mathias Heikenwalder. (2018) The immunology of hepatocellular carcinoma. Nature Immunology 19:3, pages 222-232.
Crossref
Xiaochen Wang, Haiyuan Shen, Guangyan Zhangyuan, Ruyi Huang, Wenjie Zhang, Qifeng He, Kangpeng Jin, Han Zhuo, Zechuan Zhang, Jincheng Wang, Beicheng Sun & Xiaojie Lu. (2018) 14-3-3ζ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes. Cell Death & Disease 9:2.
Crossref
Na Li, Jianing Wang, Na Zhang, Mengwei Zhuang, Zhaoyun Zong, Jiahuan Zou, Guosheng Li, Xiaoyan Wang, Huaiyu Zhou, Lining Zhang & Yongyu Shi. (2017) Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells. Cancer Immunology, Immunotherapy 67:2, pages 271-283.
Crossref
Chun-yu Huang, Ying Wang, Guang-yu Luo, Feng Han, Yong-qiang Li, Zhong-guo Zhou & Guo-liang Xu. (2017) Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma. Journal of Immunotherapy 40:9, pages 323-333.
Crossref
Ti Wen, Zhenning Wang, Yi Li, Zhi Li, Xiaofang Che, Yibo Fan, Shuo Wang, Jinglei Qu, Xianghong Yang, Kezuo Hou, Wenyang Zhou, Ling Xu, Ce Li, Jin Wang, Jing Liu, Liqun Chen, Jingdong Zhang, Xiujuan Qu & Yunpeng Liu. (2017) A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer. Cancer Immunology Research 5:7, pages 524-534.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.